A Holistic Phase Appropriate Strategy for HCP-Limits and HCP Characterization
Posted on April 30, 2018
Introduction During manufacturing of biopharmaceuticals prokaryotic and eukaryotic protein expression host systems like Escherichia coli (E. coli) and Chinese Hamster Ovary (CHO) cells generate a heterogeneous mixture of the desired therapeutic protein and a variety of endogenous host cell proteins ...
To read the full article and other articles in this issue, please register for a free account or log in.
Subscribe to our FREE newsletter